BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28182747)

  • 21. Synthesis of 5α-androstane-17-spiro-δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as inhibitors of 17β-hydroxysteroid dehydrogenases.
    Djigoué GB; Ngatcha BT; Roy J; Poirier D
    Molecules; 2013 Jan; 18(1):914-33. PubMed ID: 23344201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human 3α-hydroxysteroid dehydrogenase type 3: structural clues of 5α-DHT reverse binding and enzyme down-regulation decreasing MCF7 cell growth.
    Zhang B; Hu XJ; Wang XQ; Thériault JF; Zhu DW; Shang P; Labrie F; Lin SX
    Biochem J; 2016 Apr; 473(8):1037-46. PubMed ID: 26929402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
    Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical synthesis of fluorinated and iodinated 17β-HSD3 inhibitors and evaluation for imaging prostate cancer tumors and tissue biodistribution.
    Poirier D; Maltais R; Rousseau JA; Roy J; Phoenix S; Cortés-Benítez F; Lecomte R
    Bioorg Chem; 2022 Dec; 129():106145. PubMed ID: 36174444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
    Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
    Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity.
    Sam K; Labrie F; Poirier D
    Eur J Med Chem; 2000 Feb; 35(2):217-25. PubMed ID: 10758283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
    Maltais R; Luu-The V; Poirier D
    Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM; Tutill HJ; Purohit A; Reed MJ
    Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane-3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone.
    Ando T; Nishiyama T; Takizawa I; Ishizaki F; Miyashiro Y; Takeda K; Hara N; Tomita Y
    Sci Rep; 2016 Aug; 6():32198. PubMed ID: 27561382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
    Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
    J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase.
    He XY; Yang YZ; Peehl DM; Lauderdale A; Schulz H; Yang SY
    J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):191-8. PubMed ID: 14672739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes.
    Hu GX; Zhou HY; Li XW; Chen BB; Xiao YC; Lian QQ; Liang G; Kim HH; Zheng ZQ; Hardy DO; Ge RS
    J Steroid Biochem Mol Biol; 2009 May; 115(1-2):14-9. PubMed ID: 19429456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
    Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
    Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of steroidogenesis and steroidogenic enzyme functions.
    Luu-The V
    J Steroid Biochem Mol Biol; 2013 Sep; 137():176-82. PubMed ID: 23770321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
    Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
    J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
    Hilborn E; Stål O; Jansson A
    Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.